Trial Profile
Prospective multicenter open label study of tadalafil and ambrisentan in patients with pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary) ; Tadalafil (Primary)
- Indications Pulmonary arterial hypertension; Systemic scleroderma
- Focus Therapeutic Use
- 23 Dec 2015 New trial record